TAKARATAKARA BIO INC.

TOPICS

Strategic Change in Development of Oncolytic Virus Immunotherapy C-REV

Click here for the detail > News Release (2019/09/27)

Takara Bio to Present Clinical Data of Oncolytic Virus C-REV and NY-ESO-1·siTCR™ Gene Therapy at ESMO 2019

Click here for the detail > News Release (2019/09/24)

Takara Bio to Present Clinical Data of Oncolytic Virus C-REV and NY-ESO-1·siTCR™ Gene Therapy at ASCO 2019

Click here for the detail > News Release (2019/05/16)

Marketing Authorization Application for Oncolytic Virus Immunotherapy C-REV for Unresectable or Metastatic Melanoma Submitted in Japan

Click here for the detail > News Release (2019/03/29)

Designation Description Change of NY-ESO-1·siTCR™ gene therapy product under "SAKIGAKE Designation System"

Click here for the detail > News Release (2019/02/15)

Takara to Present Oncolytic Virus C-REV Preliminary Data from the Phase I trial Targeting Unresectable Pancreatic Cancer at ASCO-GI 2019 Congress

Click here for the detail > News Release (2019/01/16)

Canerpaturev was listed in WHO recommended International Nonproprietary Names as HF10' generic name.

Expanded Phase I Study of HF10 in Pancreatic Cancer Patients

Takara Bio is currently conducting a phase I clinical trial of Oncolytic Virus HF10(Development Code: TBI-1401(HF10) targeting pancreatic cancer in Japan, and amended its protocol to expand the trial. (Extended stage; 30 patients total)

In Japan, the combination of Gemcitabine and Nab-paclitaxel is currently the first-line treatment and TS-1® is accepted as the second- or third-line treatment for advanced pancreatic cancer. In this expansion phase, we will assess the safety and efficacy of HF10 in combination with these standard therapies.

Study Title: Phase I Study of Combination With TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Chemotherapy in Japanese Patients With Stage III or IV Unresectable Pancreatic Cancer (Clinicaltrials.gov. identifier: NCT03252808)

Takara Bio entered into an agreement for co-development/exclusive sales of NY-ESO-1 siTCR™ and CD19 CAR gene therapy with Otsuka

Click here for the detail > News Release (2018/04/09)

Announcement on product designation of NY-ESO-1 siTCR gene therapy product for synovial sarcoma under "SAKIGAKE Designation System" by the Ministry of Health, Labour and Welfare

Click here for the detail > News Release (2018/04/06)

First patient enrolled into phase I/II clinical trial of NY-ESO-1 siTCR™ gene therapy against synovial sarcoma in Japan

Click here for the detail > News Release (2018/01/19)

return to top